/
AXSM
$244.95+$3.82 (+1.59%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$12.4B
51M shares
52-week range
$96.09 – $260.19
91% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$176.69
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $50.0M | $270.6M | $385.7M | $638.5M |
| Cost of revenue | $48.9K | $37.3K | $0 | $0 | $5.2M | $26.1M | $33.3M | $47.5M |
| Gross profit | −$48.9K | −$37.3K | $0 | $0 | $44.8M | $244.5M | $352.4M | $591.0M |
| Gross margin | — | — | — | — | 89.6% | 90.4% | 91.4% | 92.6% |
| R&D | $23.5M | $53.6M | $70.2M | $58.1M | $57.9M | $97.9M | $187.1M | $183.3M |
| Operating income | −$32.8M | −$67.2M | −$99.1M | −$124.7M | −$179.8M | −$231.8M | −$280.6M | −$169.2M |
| EBITDA | −$32.6M | −$67.2M | −$100.3M | −$124.6M | −$175.4M | −$225.0M | −$272.6M | −$168.1M |
| Net income | −$31.0M | −$68.3M | −$102.9M | −$130.4M | −$187.1M | −$239.2M | −$287.2M | −$183.2M |
| Net margin | — | — | — | — | -374.0% | -88.4% | -74.5% | -28.7% |
| EPS (diluted) | -1.15 | -2.05 | -2.83 | -3.47 | -4.60 | -5.27 | -5.99 | -3.68 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $984M | $-2.14 | $-6.13–$-0.06 | 13 |
| 2027 | $1.6B | $5.50 | $-8.16–$10.42 | 12 |
| 2028 | $2.3B | $14.90 | $-4.22–$33.34 | 16 |
| 2029 | $3.1B | $25.48 | $20.03–$31.57 | 14 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Axsome Therapeutics, Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
www.axsome.com- Employees
- 925
- IPO / List date
- Nov 19, 2015
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds AXSM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 164,300 | $27.8M |
| Bridgewater Associatesas of 2026-03-31 | 56,951 | $9.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AXSM yet.
